Takeda strikes again with deal to develop antibody drug conjugate candidates

12 January 2017

Japan’s largest drug company Takeda Pharmaceutical (TYO: 4502) has signed research licensing agreements with LegoChem Biosciences (Kosdaq: 141080) in a collaboration aimed at developing new antibody drug conjugate (ADC) candidates.

This will allow Takeda access to the South Korean company’s proprietary ADC technology, ConjuAll, a platform utilizing a site-specific bio-conjugation method and a stable beta-glucuronide linker, enabling the design of homogeneous plasma stable ADCs with the potential for improved payload delivery to cancer cells.

Financial details of the deal were not disclosed, though Takeda will have an exclusive option to license global rights for the project results.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK